---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-006460"
form_type: "8-K"
ticker: "SGP"
cik: "0001778922"
company_name: "SpyGlass Pharma, Inc."
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:55:37.115296+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# SpyGlass Pharma closes IPO, raises $172.5M at $16.00/share

## Summary
- Closed IPO of 10,781,250 shares (incl. full exercise of underwriters' option for 1.4M additional shares) at $16.00/share.
- Aggregate gross proceeds of $172.5 million before underwriting discounts and offering expenses.
- Common stock began trading on Nasdaq Global Select Market under ticker SGP on February 6, 2026.
- Habib Dable appointed to board as Class I director and to compensation committee; receives standard director compensation and option grant.

## SEC filing metadata
- accession: 0001628280-26-006460
- form_type: 8-K
- ticker: SGP
- cik: 0001778922
- company_name: SpyGlass Pharma, Inc.
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/0001628280-26-006460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/spyglassclosing8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-006460
- JSON: https://secwatch.observer/filing/0001628280-26-006460.json
- Plain text: https://secwatch.observer/filing/0001628280-26-006460.txt

## Source-grounded claims
- claim_id: 45e9752be11d8deb14a89b94a3d1d3ea85fd846b
  claim: SpyGlass Pharma, Inc.: Adopted amended and restated bylaws effective as of the same date (effective 2026-02-09).
  evidence_excerpt: Effective as of February 9, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the completion of the IPO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/0001628280-26-006460-index.htm
- claim_id: 5bdb966b3ab5595f3e19ce9e87c36e102394e57e
  claim: SpyGlass Pharma, Inc.: Filed amended and restated certificate of incorporation in connection with IPO completion (effective 2026-02-09).
  evidence_excerpt: On February 9, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the completion of the IPO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/0001628280-26-006460-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.